Background. Only a minority of women with human papillomavirus (HPV) infection eventually develop cervical cancer, which suggests that host immune mechanisms play a role in the disease. HLA polymorphisms have been linked to the risk of cervical cancer, but very little is known about the role that they play in the acquisition and persistence of HPV infection.
cluding exposure to host immune and genetic factors, are implicated in cervical carcinogenesis [2] . One such factor is the major histocompatibility complex (MHC), which plays a critical role in determining resistance to infections.
Located on chromosome 6p, the MHC comprises a tightly linked cluster of at least 200 genes that encode for the cell-surface HLA molecules in class I (A-C) and class II (DR, DQ, and DP) [3] . Class I genes are expressed on all nucleated cells and function to present endogenous antigens to CD8 + T cells. Class II genes are expressed only by "professional" antigen-presenting cells, such as macrophages and lymphocytes, and function to present exogenous antigens to CD4 + T cells [3] .
Several loci of the MHC are highly polymorphic, which permits efficient recognition and presentation of a very diverse range of foreign antigens [4] . It has been postulated that an individual's repertoire of MHC alleles may be associated with differential susceptibility to diseases caused by infectious agents [5] .
A review of several studies involving different ethnic groups has confirmed the significant role that MHC polymorphisms play in cervical carcinogenesis [5] . Several class II allelesnotably, DQB1*03 and the DRB1*15-DQB1*0602 haplotype and its individual alleles-have been found to be positively associated with invasive cervical cancer [5] . This finding is in contrast with the situation for the DRB1*13 alleles and their haplotypes with DQB1*0603, which consistently have been found to be negatively associated with cervical neoplasia. The role played by class I alleles has not been determined, but positive associations between the B7 allele and cervical neoplasia have been reported in studies conducted in North and Central America [5] .
It is not clear what biological mechanisms mediate the effects that HLA polymorphisms have on cervical carcinogenesis. Research suggests a strong link between an inefficient immune response-in particular, inefficient cell-mediated and innate immunity, both of which involve class I and II HLA allelesand susceptibility to HPV infection. HPV infections are more prevalent and more likely to persist in immunosuppressed individuals, such as patients with AIDS [6] . There is evidence that MHC class II is involved in rabbit and mouse immunity, manifested as wart regression and response to HPV epitopes [7, 8] . However, the role that MHC polymorphisms play in the acquisition and persistence of HPV infection in humans remains unclear.
The present study used data and samples from a cohort study of the natural history of HPV infection to examine the relation between certain HLA alleles (the HLA class I B*07 allele and the HLA class II DRB1*13, DRB1*1501, DQB1*0602, and DQB1*03 alleles) and the risk of occurrence and persistence of HPV infections. These alleles and their related haplotypes were chosen, at the outset of the study, as potential targets for identifying the effects that MHC has in mediating the risk of HPV infection.
SUBJECTS AND METHODS
The McGill-Concordia Cohort Study. The present investigation was conducted as part of the McGill-Concordia Cohort Study, a prospective cohort study of the natural history of HPV infection and cervical neoplasia in female university students in Montreal, Canada. The study methods have been described in detail elsewhere [9] . In brief, women attending either the McGill or Concordia University health-services clinics were eligible to participate if they intended to remain in Montreal during the next 2 years and, during the previous 12 months, had not required treatment for cervical disease. Recruitment was initiated in November 1996 and was completed in January 1999.
All eligible women were asked to return to the clinic every 6 months during a period of 2 years, for a total of 5 visits. At each visit, samples of endocervical and ectocervical cells were collected by use of 2 Accelon cervical biosamplers (Medscand). A Pap smear was prepared with the first sampler, and the remaining cells along with cervical cells collected with the second sampler were used for HPV DNA testing. DNA was purified by use of QIAamp columns (Qiagen) and was tested for the presence of HPV DNA by the MY09/MY11/HMB01 polymerase chain reaction (PCR) protocol [9] . HPV typing of the amplified products was performed by line-blot assay (Roche Molecular Systems), which permitted probing for 13 oncogenic or highrisk HPV (HR-HPV) types-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68-and 14 unknown or low-risk (LR-HPV) types -6, 11, 26, 40, 42, 53, 54, 55, 57, 66, 73, 82, 83 , and 84 (for details, see [9, 10] ). Amplification of b-globin DNA by PC04 and GH20 primers was used to show the absence of inhibitors and the integrity of processed DNA. To ensure that contamination was avoided, negative, weakly positive, and strongly positive controls were included in all amplification runs.
At enrollment, a self-administered questionnaire was used to collect information on sociodemographic variables, ethnicity, smoking and drinking habits, reproductive history, and sexual practices. At each subsequent visit, information on sexual behavior since the preceding visit also was collected. The study protocol was approved by the Research Ethics Boards of all partnering Montreal universities. Written informed consent was obtained from all participants.
HLA genotyping. HLA alleles were typed on the basis of purified DNA from the enrollment cervical specimens, by a PCR technique using sequence-specific primers (PCR-SSP), according to a well-established procedure [11] . In this assay, pairs of oligonucleotides, designed on the basis of HLA polymorphic sequences, were used as primers for amplification of class I (B*07) and class II (DQB1*03, DQB1*0602, DRB1*13, and DRB1*1501) alleles. Amplification control primers giving rise to a 796-bp fragment from the third intron of HLA-DRB1 were included in PCR reactions, to verify successful amplification. Negative and positive controls were included in all amplification runs. Visualization of the PCR product was achieved by electrophoresis performed on 1% agarose gel stained with ethidium bromide and visualized under UV illumination.
Coded specimens were blind-tested by investigators without knowledge of other laboratory or risk-factor information on the subjects.
HLA genotyping was attempted for all women who participated in the study for at least 3 visits. However, women who at 2 consecutive visits tested positive for the same HPV type (i.e., who had persistent infections) were included even if they participated only for these 2 visits. Enforcing these rules led to the exclusion of 62 women. Another 35 women were excluded because their samples were negative for both HPV and b globin, indicating insufficient intact DNA for PCR. The remaining 524 women (i.e., 84% of the 621 enrolled participants) were genotyped for the 5 HLA alleles, and all were successfully typed for the DQB1*03, DQB1*0602, DRB1*13, and DRB1*1501 alleles; because of insufficient DNA, 5 women could not be typed for B*07 and therefore were excluded from the analyses for that allele. Statistical analysis. The present study examined 2 binary outcomes: cumulative risk of HPV infections and HPV persistence. When cumulative risk of HPV infections was considered, women who tested positive at least once for any HPV type were compared with those who tested negative at enrollment and remained negative at all follow-up visits. To assess whether any associations were dependent on the specific HPV type causing the infection, the study also examined cumulative risk of HPV infections for the following viral types, grouped hierarchically with respect to oncogenic potential: (1) LR-HPV positivity comprised women who tested positive at least once for any LR-HPV type but never tested positive for an HR-HPV type; (2) HR-HPV positivity comprised women who tested positive at least once for any HR-HPV type, regardless of whether an LR-HPV type had been detected; and (3) HPV-16 positivity comprised women who tested positive at least once for HPV-16. In all analyses, women who tested negative for HPV at all visits comprised the comparison group.
For analyses of HPV persistence, women who tested positive for the same HPV type at 2 or more consecutive visits were compared with those who were defined as having transient infections (i.e., who either had tested positive only once or had tested positive more than once at nonconsecutive visits). In analyses of HR-HPV persistence, women who tested positive for the same HR-HPV type at 2 or more consecutive visits were compared with women with transient HR-HPV infections.
The x 2 and Kruskall-Wallis tests were used to compare the distribution of sociodemographic and other risk factors in cases versus controls (as defined by HPV positivity and persistence; table 1), as well as between carriers of the various alleles. Separate multivariate unconditional logistic regression models were used to evaluate the association between each HLA allele and the occurrence and persistence of HPV infections, while adjusting for potential confounders. Ethnicity was considered a confounder because of associated genetic and lifestyle and behavioral factors and was adjusted for a priori. Women were classified into the following 5 groups, according to self-reported ethnic background: English white, French white, other white, Asian, and black. In addition, the possibility of effect modification by ethnicity was assessed by contrasting models with and without the interaction terms, by a likelihood-ratio test.
The present study also assessed confounding by other cofactors, using a 10%-change-in-estimate criterion for the crude estimates. The factors considered included age, parity, marital status, socioeconomic status, education, cigarette smoking, oral-contraceptive use, age at first intercourse, condom use, lifetime and last-year number of sex partners, lifetime frequency of Pap tests, and previous diagnosis of sexually transmitted infection. Only age at first intercourse met the 10%-changein-estimate criterion and therefore was included, in addition to ethnicity, in all adjusted models.
To estimate the effect of each allele, the study compared subjects who tested positive for a particular allele versus those who tested negative for it. For haplotypes, the comparison was between subjects who tested positive for both alleles that comprise the specific haplotype versus subjects who tested negative for both of them. The choice of haplotypes, DRB1*1501-DQB1*03 and DRB1*1501-DQB1*0602, was made a priori, either on the basis of substantive knowledge of alleles that are in linkage disequilibrium or, alternatively, by identification of alleles that appeared together in relatively high frequency in this population.
To explore the possibility that the effect of certain alleles depended on the level of exposure to HPV, the analysis was repeated after being restricted to women who had a high likelihood of exposure to HPV (HLE-HPV), defined on the basis of a woman's sexual history. Women were considered to be in the HLE-HPV subgroup if they either were р17 years old when they had first had sexual intercourse or if they had had 15 lifetime partners. These cutoff points were chosen on the basis of the natural quartiles of the data, so that women in the uppermost quartile for the variable "number of sex partners" or, alternatively, women comprising the lowermost quartile for the variable "age at first intercourse" were selected into the HLE-HPV subgroup. All analyses involving this population were adjusted for ethnicity and current age. Because of the small number of women in each of the outcome categories, haplotype analyses of this subgroup were not performed. All statistical analyses were performed by use of Stata software (version 8.1; Stata). All tests of significance were 2-sided. Using a significance level of , the study calculated that, P ! .05 for an exposure variable with a prevalence of 10% in this population, there was adequate (i.e., 80%) power to detect an odds ratio [OR] of 11.7. For a more common exposure (i.e., 50% prevalence), a weaker association-namely, OR у1.4-could be detected.
RESULTS
Descriptive statistics. Table 1 shows the distribution of baseline demographic and sexual-history variables, according to HPV status. The average age of the entire cohort was 22.6 years (range, 17-45 years). Most (i.e., 86%) of the participants were white. Only 44% of the women remained persistently negative for HPV throughout follow-up; the remaining women acquired either persistent (37%) or transient (19%) infections. The distribution of age, ethnicity, and socioeconomic status did not differ with respect to HPV status. As expected, HPV-positive women were more likely to have been younger at first intercourse and to have had more lifetime sex partners and fewer Pap tests. The distributions of sociodemographic variables for the women who were not HLA typed (and who therefore were not included in analysis) were similar to those of the women who were typed (data not shown). During follow-up, there were 30 incident neoplasias-28 low-grade squamous intraepithelial lesions and 2 high-grade squamous intraepithelial lesions.
Prevalence of HLA alleles and haplotypes. Overall, DQB1*03 was the most prevalent allele (frequency, 64%), as shown in NOTE. CI, confidence interval; HR-HPV, high-risk HPV; OR, odds ratio. a Defined as at least 2 consecutive occurrences of the same HPV type. b Defined as at least 2 consecutive occurrences of the same HR-HPV type. c Adjusted for age at first intercourse and ethnicity, when the entire cohort was analyzed, and for age and ethnicity, when the HLE-HPV subgroup of women was analyzed. d Analyses were restricted to women whose age at first intercourse was р17 years or who had had у5 lifetime sex partners. table 2. The least prevalent allele (frequency, 15%) was the class I B*07 allele. The prevalence of the various alleles did not vary significantly by ethnicity; DRB1*1501 was more prevalent in black women, but the numbers were small. As expected, the DRB1*1501 and DQB1*0602 alleles were strongly positively correlated (Kendall's ; ). DRB1*1501 t-b p 0.89 P ! .001 and DQB1*03 were not strongly correlated in this population (Kendall's ; ). The prevalence of the t-b p 0.12 P p .006 DRB1*1501-DQB1*0602 haplotype ranged from 6%, in Asians, to 25%, in English white subjects.
HPV positivity. Table 3 shows the results for the association between cumulative risk of HPV infections and each of the examined alleles and haplotypes. The DRB1*13 allele was positively associated with cumulative risk of HPV infections (OR, 1.7 [95% confidence interval {CI}, 1.0-2.8]), for HR-HPV (OR, 1.6 [95% CI, 0.9-2.8]), and for HPV-16 (OR, 2.0 [95% CI, 0.9-4.4]). These associations were generally stronger and more statistically significant in the HLE-HPV subgroup. The DQB1*03 allele was consistently associated with a lower cumulative risk of HPV infections, but none of the associations was statistically significant.
Generally, all other class II alleles and haplotypes were associated with little or no increase in the cumulative risk of HPV infections. The only statistically significant associations were found between cumulative risk of HPV-16 infections and the DRB1*1501 allele (OR, 2.1 [95% CI, 1.1-4.1]) and its corresponding haplotype DRB1*1501-DQB1*0602 (OR, 2.0 [95% CI, 1.0-4.1]). B*07 was consistently associated with an increased risk for all outcomes, although none of the associations was statistically significant. In a model with mutual adjustment for all alleles, the results remained essentially the same (data not shown).
HPV persistence. Table 4 shows the results for the association between persistent HPV infections and the investigated HLA alleles and haplotypes. Generally, there was no evidence of an association between HPV persistence and any class II allele or haplotype. The class I B*07 allele was negatively associated with persistent HPV (OR, 0.7 [95% CI, 0.4-1.4]) and NOTE. Simulations showed, for instance, that for the DRB1*13 allele, which was positively associated with cumulative risk of HPV infections in the entire cohort, one would encounter an estimated OR у the observed OR (i.e., 1.7) in only 2.1% of 1000 random permutations of the data set (for details, see the main text). HPV, human papillomavirus; HR-HPV, high-risk HPV; LR-HPV, low-risk HPV; OR, odds ratio.
persistent HR-HPV infections (OR, 0.6 [95% CI, 0.3-1.3]). However, neither of these associations was statistically significant.
Multiple comparisons. Although the present study's analyses are not excessive in terms of the numbers of associations examined, it assessed whether multiple comparisons could have inflated the study's false-detection rate; to do so, it used computer simulations to calculate the proportion of hypothetical studies that would produce an OR equal to or greater than that observed in this population, assuming that no association exists.
The number of associations expected by chance was estimated by use of random data sets generated from the original data. The original data were divided into 2 blocks; the first block comprised the HPV-exposure variables (i.e., all 5 alleles) and any confounding variables, whereas the second included the outcome variables. Then the 2 blocks were randomly mixed. The result was a data set that preserved information on related variables, although the outcomes were randomly distributed among samples. All analyses were repeated on 1000 such random data sets, and the number of associations statistically significant at the level [12] were counted. As shown in P ! .05 table 5, most of the observed associations were unlikely to have occurred by chance.
DISCUSSION
The present study found that the class II allele DRB1*13 was associated with an increased occurrence of HPV infections, especially in the HLE-HPV subgroup of women. On the other hand, the DQB1*03 allele was consistently associated with a lower cumulative risk of HPV infections. None of the examined alleles seemed to influence the risk of HPV persistence, except for B*07, which was negatively associated with persistent HPV and HR-HPV infections, although neither of these associations was statistically significant.
The present study's findings of positive associations between HPV infections and the DRB1*13 allele seem to be at odds with several previous analyses of diverse populations, analyses that have found a statistically significant inverse association between DRB1*13 (or the allele in the haplotype combination with DQB1*0603) and cervical cancer [13] [14] [15] [16] [17] [18] . Thus far, only a report by Maciag et al. [12] has described results that, with respect to DRB1*13, are similar to those of the present study; that study, which used a longitudinal design with repeated measurements of HPV to examine the relation between various MHC polymorphisms and acquisition and persistence of HPV infections in the Ludwig-McGill cohort of Brazilian women [12] The positive associations observed both by the present study and by Maciag et al. [12] could have resulted from a cosegregating allele that neither study accounted for. It is also conceivable that the DRB1*13 allele could exert its protective effect against cervical neoplasia at a later stage of carcinogenesis, although this possibility seems less likely, given that neither study found DRB1*13 to be associated with viral persistence. It also has been suggested that certain HLA associations could be population specific, which would imply a more complex etiological model involving possible interactions between host factors (e.g., MHC genes and other host genes) and virus factors (e.g., HPV variants) [12, 19] . In one study, a particular molecular variant of HPV-16 was found more often in patients positive for HLA-B7 than in those negative for B7 [20] . The discrepancy between the results of the present study and those of previous studies may also reflect differences between repeated-measurement longitudinal designs, such as those which were used in the present study, and case-control designs, which dominate the field: because case-control studies are typically limited to a single cross-sectional measurement of HPV positivity, they are more susceptible to misclassification of HPV status.
In the present study, women with the DQB1*03 allele were consistently at lower risk for HPV infection, although none of the associations was statistically significant; this finding is consistent with the results of Maciag et al. [12] , who described an inverse association between DQB1*0301 and persistent HPV infection or HPV positivity. Cervical-cancer studies prior to these 2 studies had shown inconsistent results with respect to the effect of DQB1*03, with some studies reporting positive associations [13, [21] [22] [23] ] and others reporting negative or null associations [17, 18, 24, 25] .
The results of the present study suggest that women with B*07 are at higher risk for HPV positivity, although the findings were not statistically significant. This allele has previously been implicated as a risk factor for cervical neoplasia [26] . That study found that the B*07 allele in the haplotype with DQB1*0302 was associated with an 8-fold increase in the risk for high-grade cervical neoplasia and cancer; similarly, B*07 alone has been found to be associated with a 5-fold increase in the risk for low-grade cervical neoplasia and HPV infections [17, 26] .
The associations observed in the present study tended to be stronger with respect to HPV-16 positivity, an observation that is in accordance with previous demonstrations that the HLAmediated immune mechanisms are HPV-type specific [17, 18, 26, 27] . The present study's results show that DRB1*1501 both alone and in the haplotype with DQB1*0602 is more likely to be found in women with HPV-16, findings that are consistent with those of several studies examining cervical cancer in different ethnic populations [14, 16, 18, 22, 25] .
The present study found no significant associations between HPV persistence and any of the examined alleles; this suggests that MHC polymorphisms may be more relevant for acquisition of HPV infections than for their clearance. The only other study [12] that evaluated the effect that HLA alleles have on persistence cannot be directly compared with the present investigation, because that study contrasted the persistent-infection categories with those including women who were persistently negative; in contrast to the method of the present study, no direct comparison of transient and persistent infections was made. The present study's finding of no association between HPV persistence and any of the examined alleles suggests that the HLA complex acts earlier in the etiological pathway, perhaps at the stage of host immune recognition of the virus and acquisition of infection rather than at the stage of clearance of the infection; however, the present study lacked sufficient power to detect small associations, especially in the case of rare alleles.
The present study also had other limitations. Persistence was defined as the presence of the same HPV type at 2 or more consecutive visits. Because these visits were, on average, ∼6 months apart, it is possible that some of these persistent cases were in fact transient recurring infections. False-negative HPV tests could result in the opposite problem, whereby persistent cases are judged to be transient. In both cases, the resulting misclassification of the outcome variable is likely nondifferential and therefore would increase the study's type II error rate. On the other hand, the study attempted to minimize multiple comparisons, which could increase the study's type I error rate, by both limiting the analyses to alleles known for their consistent association with cervical cancer and emphasizing findings that were consistent in the present analyses.
The results of the present study suggest that HLA polymorphisms may play a role in the immune response to HPV infections and that HLA-mediated effects may act predominantly at the acquisition stage of infection. Studies of the associations between HLA alleles and cervical neoplasia have unveiled important predictive markers of risk. It remains to be seen, however, whether these associations can be corroborated in future cohort studies focusing exclusively on HPV end points. Such corroboration would expand our understanding of the mechanism whereby particular alleles or haplotypes mediate risk.
